

22 December 2021 EFPIA Japan

EFPIA Japan Appoints Dr. Takeo Morooka as Director General

TOKYO – 22 December 2021 – EFPIA Japan announced today that Dr. Takeo Morooka has been appointed Director General of EFPIA Japan, effective 15 December 2021. Former Director General Yasuhiro Nishimi continues to serve as Chair of Pricing and Economics Committee.

Upon the appointment, Dr. Morooka says, "The pharmaceutical industry has had a paramount role in fighting against the pandemic by leveraging years of investment in vaccine and therapeutic technology platforms. We now recognize the power of science and innovation and how critical public-private-academia collaboration is in addressing healthcare challenges. We believe that both public and private stakeholders have an important role to play in strengthening our healthcare systems and fostering innovation. To this end, I look forward to working closely with our stakeholders."

EFPIA Japan Chair Iwaya says, "It is a pleasure to have the Director General with experience in both the industry and government and as a clinician onboard to EFPIA Japan. With the addition of Dr. Morooka, we will further enhance our initiatives as an industry group and contribute to discussions to improve healthcare systems ultimately to serve the needs of healthcare and patients in Japan."

After graduating from Kyoto University School of Medicine in 1994, Dr. Morooka served as plastic surgeon at Kobe City General Hospital and other hospitals. He joined the Ministry of Health and Welfare in 1998, graduated from the Harvard School of Public Health in 2001, and was seconded to the World Health Organization Headquarters in Geneva in 2002 as External Affairs Officer. After the lift of his secondment from the Ministry of Health, Labour and Welfare in 2005, he served as Medical Officer at the WHO Headquarters. He had worked at International University of Health and Welfare since 2007, Covidien Japan since 2010, and MSD K.K. since 2015 as senior management.



About EFPIA Japan (http://efpia.jp/)

Established in April 2002, EFPIA Japan represents 21 R&D-based European pharmaceutical companies operating in Japan. In 2020, combined sales from the member companies accounted for roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to "Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines". EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations)

(http://www.efpia.eu)

EFPIA, EFPIA Japan's partner organisation, is headquartered in Brussels and represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA provides the voice of companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.

Contact:

Yuko Kidoguchi EFPIA Japan Messaging & Communications Committee 1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268 Bayer Holding Ltd. Tel: 03-6266-7757 Email: yuko.kidoguchi@bayer.com